Table 4 Characteristics of patients with either PR and/or long-term survival in excess of 24 months
Age at enrolment and sex | Race | Cause/ cirrhosis (Child– Pugh) | Previous treatment/ resection | AFP↑/ pathology confirmation | Extra hepatic metastasis/ portal thrombosis | BCLC | Okuda | CLIP | MELD | Progression before study entry/ response | Treatment duration/ overall survival (months) | Cause of death | Treatment received after completion of experimental therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
62 M | Caucasian | Hep C/yes (A5) | Yes/no | Yes/yes | No/no | B | 1 | 0 | 6 | Yes/N/A | 2.0/32.0 | Tumour progressed | Systemic chemotherapy |
67 F | Caucasian | Hep C/yes (B9) | Yes/no | Yes/yes | No/no | C | 2 | 2 | 11 | Yes/PR | 11.7/11.7 | GI bleed | None |
30 M | Black | NOS/no | Yes/es | No/yes | No/no | B | N/A | N/A | N/A | No/PR | 13.5/37.6 | Tumour progressed | Chemoembolisation and systemic chemotherapy |
61 M | Caucasian | Hep C/yes (A5) | Yes/no | No/no | No/no | C | 1 | 1 | 6 | Yes/SD | 26.8/26.8 | COPD | None |
56 M | Caucasian | Hep B/C/yes (A5) | No/no | Yes/no | No/no | B | 1 | 0 | 10 | Yes/SD | 4.9/50.3 | Tumour progressed | Chemoembolisation |
63 M | Caucasian | Hep C/yes (A5) | Yes/no | Yes/no | No/no | C | 1 | 1 | 4 | Yes/PR | 4.9/14.3 | Tumour progressed | None |
76 F | Caucasian | Hep C/yes (A5) | No/no | No/no | No/yes | C | 1 | 1 | 6 | Yes/SD | 44.6/44.6 | Tumour progressed | None |
76 F | Caucasian | Hep C/yes (A5) | No/yes | No/yes | Yes/yes | C | 1 | 1 | 6 | Yes/PR | +58.0/+58.0 | On therapy | Still receiving experimental treatment |
